Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Reshape Lifesciences Inc (RSLS)

Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,353
  • Shares Outstanding, K 2,386
  • Annual Sales, $ 8,010 K
  • Annual Income, $ -7,130 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.16
  • Price/Sales 0.95
  • Price/Cash Flow N/A
  • Price/Book 1.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -193.23
  • Most Recent Earnings $18.98 on 05/20/25
  • Next Earnings Date 11/13/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1,182.51
  • Growth Rate Est. (year over year) +184.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.87 +109.63%
on 08/11/25
4.65 -15.70%
on 08/14/25
+1.53 (+64.02%)
since 07/14/25
3-Month
1.87 +109.63%
on 08/11/25
8.29 -52.71%
on 06/03/25
-2.13 (-35.21%)
since 05/14/25
52-Week
1.87 +109.63%
on 08/11/25
303.25 -98.71%
on 09/23/24
-254.04 (-98.48%)
since 08/14/24

Most Recent Stories

More News
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that...

HIND : 4.01 (-1.47%)
RSLS : 15.68 (+22.50%)
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Effective as of Commencement of Trading on August 15, 2025

RSLS : 15.68 (+22.50%)
Vyome Announces New Board of Directors with Deep MIT and AI Ties

Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 ...

RSLS : 15.68 (+22.50%)
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Expected to be Effective as of Commencement of Trading on August 15, 2025

RSLS : 15.68 (+22.50%)
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR...

RSLS : 15.68 (+22.50%)
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will...

RSLS : 15.68 (+22.50%)
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2,...

RSLS : 15.68 (+22.50%)
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

RSLS : 15.68 (+22.50%)
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

RSLS : 15.68 (+22.50%)
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

RSLS : 15.68 (+22.50%)

Business Summary

ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA.

See More

Key Turning Points

3rd Resistance Point 6.63
2nd Resistance Point 5.64
1st Resistance Point 4.78
Last Price 15.68
1st Support Level 2.93
2nd Support Level 1.94
3rd Support Level 1.08

See More

52-Week High 303.25
Fibonacci 61.8% 188.12
Fibonacci 50% 152.56
Fibonacci 38.2% 117.00
Last Price 15.68
52-Week Low 1.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar